Testosterone Cypionate for Gender-Affirming Care: Monitoring Requirements

The direct answer

Testosterone cypionate has no FDA-approved indication for gender-affirming care; it is approved only for testosterone replacement in cisgender men with confirmed hypogonadism. Its use in masculinizing GAHT is off-label but is supported by the Endocrine Society's clinical practice guideline and the WPATH Standards of Care, both of which call for baseline laboratory testing, testosterone and hematocrit checks roughly every three months during the first year of therapy, and ongoing screening for erythrocytosis, lipid changes, and cardiovascular risk factors afterward. The strongest, most consistently reported monitoring signal across the literature is a rise in hematocrit; other numeric estimates in circulation (exact percentages for cardiovascular events, depression score changes, or endometrial findings) come from individual cohort studies of varying size and should be confirmed against the primary paper before being used to counsel a specific patient.

What testosterone cypionate is, and what it is not approved for

Testosterone cypionate is a long-acting injectable ester of testosterone, sold under brand names including Depo-Testosterone, administered intramuscularly or (off-label) subcutaneously. It belongs to the androgen class of hormones. The FDA label approves it only for males with hypogonadism caused by primary testicular failure or hypothalamic-pituitary dysfunction. There is no FDA indication for gender-affirming hormone therapy, and the label's dosing and monitoring language reflects a cisgender male hypogonadal population rather than a transitioning transmasculine population, whose starting hormonal physiology, target endpoints, and body composition goals differ.

Off-label prescribing here is not fringe practice. Major clinical bodies, including the Endocrine Society and WPATH, publish guideline-level recommendations specifically for this use. But because the FDA label was not built around this population, dose titration, lab targets, and side-effect surveillance draw on guideline consensus and observational data rather than on-label pharmacokinetic study in transgender patients.

Why the monitoring differs from hypogonadism treatment

In cisgender men treated for hypogonadism, testosterone is restoring levels toward a baseline the person's body previously maintained. In masculinizing GAHT, testosterone is shifting an estrogen-dominant physiology toward androgen dominance, which affects erythropoiesis, lipid handling, and the endometrium in ways that are not identical to simple replacement. This is the practical reason guidelines ask for closer surveillance, particularly of hematocrit, during the first year.

The most reproducible finding across observational studies of transmasculine patients on testosterone is a rise in hematocrit that in some patients crosses into clinically significant erythrocytosis. Reported rates of erythrocytosis vary meaningfully between studies depending on dose, injection frequency, route, and how "elevated" was defined, so a single precise incidence figure should not be treated as fixed. What is consistent across studies and guidelines is the direction of the effect and the recommended response, discussed below.

Baseline labs before the first injection

A baseline panel before starting therapy is what allows a clinician to interpret every later result. Guideline-consistent baseline testing generally includes:

• Complete blood count with hematocrit and hemoglobin
• Comprehensive metabolic panel, including AST, ALT, and creatinine
• Fasting lipid panel
• Fasting glucose or HbA1c
• Total testosterone and estradiol

A pregnancy test is appropriate for anyone with a uterus who has been sexually active with sperm-producing partners, regardless of reported contraception, because testosterone carries fetal risk. Baseline DEXA scanning is not universally required but is reasonable to consider for patients with a history of prolonged amenorrhea before starting testosterone, disordered eating, or chronic corticosteroid use. Some clinicians also obtain baseline LH, FSH, SHBG, or free testosterone to characterize the starting hormonal axis, though these are not uniformly required by guideline.

Monitoring during the first year

The first year is when most dose titration happens and when physiological change is fastest, which is why monitoring is more frequent during this window.

Total testosterone is typically checked around three, six, nine, and twelve months, drawn as a trough level (just before the next scheduled injection) so that results are comparable over time. The Endocrine Society guideline's commonly cited trough target is 400 to 700 ng/dL, the typical adult male reference range; levels persistently below that may indicate underdosing, and levels persistently above it raise erythrocytosis risk without added benefit to virilization.

Hematocrit is generally checked at each of these same visits during year one. Guideline-consistent thresholds used in practice are a dose adjustment (lower dose, or the same total dose split into more frequent smaller injections) once hematocrit exceeds roughly 50%, and temporary discontinuation until hematocrit falls back below that threshold if it exceeds roughly 54%, followed by restarting at a lower dose. These thresholds are guideline-level clinical practice points rather than numbers each individual study reproduces exactly, and any specific action still needs to come from the treating prescriber based on the full clinical picture.

Lipid panels and liver enzymes (AST, ALT) are commonly rechecked at baseline, six months, and twelve months. Cohort studies of transmasculine patients on testosterone have documented HDL decline and modest LDL increases during the first year; however, the specific magnitude varies across studies and should be verified in the original source before citing precise values. Testosterone cypionate administered by injection rarely causes clinically significant liver enzyme elevation, presenting substantially lower hepatotoxicity risk compared to oral 17-alpha-alkylated androgens like methyltestosterone.

Blood pressure should be checked at every clinical visit, not on a lab schedule, because testosterone can raise blood pressure gradually over the first year.

Maintenance monitoring after the first year

Once testosterone levels and side-effect labs have been stable for a period on an unchanged dose, most guidelines support spacing surveillance out to every six to twelve months. A reasonable maintenance panel repeats trough testosterone, CBC with hematocrit, fasting lipids, hepatic panel, and fasting glucose or HbA1c, with blood pressure checked at every visit regardless of lab timing.

Estradiol monitoring generally becomes optional after year one once menses have stopped. Persistent menstrual bleeding beyond roughly six months of adequately dosed testosterone (trough above 400 ng/dL) is a reason for gynecologic evaluation rather than an automatic dose increase, since bleeding on adequate testosterone is not primarily a dosing problem.

Cardiovascular risk: what is established and what is not

Cardiovascular risk in transmasculine patients on long-term testosterone is an area with real uncertainty, and this is a place where readers should not expect a settled answer. Observational cohort data comparing transgender men on testosterone to cisgender comparison groups have generally not shown a clear, statistically robust increase in major cardiovascular events over follow-up periods in the range of several years, but confidence intervals in these studies are often wide, and studies extending meaningfully beyond ten years of exposure are still limited. A finding of "no significant difference" in a study with a wide confidence interval is not the same as "proven safe," and readers should not treat it that way.

For practical risk management, clinicians typically apply standard cardiovascular risk calculators (such as the ASCVD Pooled Cohort Equations) using current lab values, since there is no validated cardiovascular risk tool built specifically for transgender populations. Which sex category to select in these calculators is itself a judgment call clinicians make based on the patient's current hormonal profile, since lipid and blood pressure patterns shift after transition.

Bone density

Continuous, adequately dosed testosterone therapy is generally understood to maintain bone mineral density in transmasculine patients, and routine DEXA scanning before age 50 is not typically required in the absence of other risk factors. The scenario that raises concern is a treatment gap: stopping testosterone without another source of sex hormones (either residual ovarian function or exogenous estrogen) creates a sex-steroid deficit that can accelerate bone loss. Guideline-consistent practice recommends DEXA screening for patients who have discontinued testosterone for more than about 12 months, patients who had an oophorectomy and later stopped testosterone, or anyone with additional fragility fracture risk factors.

Reproductive organ screening does not stop

Testosterone therapy does not remove the need for organ-specific cancer screening in patients who retain a cervix, uterus, or ovaries. General population cervical cancer screening guidelines still apply. Vaginal atrophy from testosterone can make speculum exams uncomfortable; a pediatric speculum, self-swab HPV collection where available, or topical vaginal estrogen (which does not meaningfully raise serum estradiol) can reduce discomfort without compromising screening.

Routine transvaginal ultrasound of the endometrium is not typically required unless a patient has unexpected vaginal bleeding after menses have stopped on adequate testosterone dosing. Reported findings on endometrial thickness and hyperplasia risk during testosterone therapy come from individual case series; the specific percentages reported in any one study should be checked before being repeated as a general reassurance to a patient with abnormal bleeding.

Mental health monitoring is part of the picture, not separate from it

Guideline-level care includes structured mental health check-ins, not just labs. A reasonable practice is a validated screening instrument such as the PHQ-9 for depression and GAD-7 for anxiety at each visit during year one and at least annually afterward. Multiple studies and reviews report improvement in depression and anxiety symptoms with GAHT, generally emerging within the first several months of therapy, though the precise magnitude of improvement varies across the reviewed literature and depends heavily on study population and design. If mood symptoms worsen despite testosterone levels in target range, the more useful next step is evaluating for external stressors, minority stress, or a co-occurring psychiatric condition, not assuming the hormone dose is wrong.

Does the injection route change the monitoring plan?

Subcutaneous injection of testosterone cypionate has become common in GAHT for comfort and ease of self-administration, even though the FDA label specifies intramuscular use, making subcutaneous administration itself an additional off-label variation. Comparative pharmacokinetic studies in transmasculine patients have generally found similar testosterone levels, hematocrit, and lipid effects between subcutaneous and intramuscular administration at comparable doses. Practically, this means the monitoring schedule above does not change based on route; the same labs at the same intervals apply either way. The main advantage of subcutaneous dosing is adherence, and better adherence tends to produce more interpretable trough levels.

Drug interactions that change monitoring frequency

A few interactions are clinically relevant enough to change lab timing rather than just being listed as theoretical:

• Warfarin or other anticoagulants: testosterone can increase anticoagulant sensitivity. INR should be checked more frequently, for example every two weeks, when testosterone is started in a patient already on warfarin.
• Corticosteroids: concurrent use raises fluid retention risk and can worsen glucose tolerance, which is a reason to check fasting glucose or HbA1c more often than the standard six-month interval.
• Insulin or oral hypoglycemic agents: testosterone can improve insulin sensitivity over time, which may require a dose reduction in patients with diabetes. The prescribing information for testosterone cypionate specifically warns about hypoglycemia risk in patients taking diabetes medications.

Evidence boundary: what is established, what is plausible, what is not settled

Established, per the FDA label and guideline consensus: testosterone cypionate is approved only for hypogonadism in cisgender men; its use in GAHT is off-label; hematocrit rises during testosterone therapy and needs monitoring; blood pressure should be checked at every visit; continuous adequate testosterone dosing supports bone density; general population cancer screening still applies to retained organs.

Plausible but not fully settled: the exact incidence of erythrocytosis, the precise magnitude of lipid shifts, and the degree of mental health improvement all vary across studies and populations, and single-study numbers should not be presented to a patient as a universal probability.

Not established: long-term (beyond roughly a decade) cardiovascular event risk in transmasculine patients on testosterone, and any transgender-specific cardiovascular risk calculator. Readers and clinicians should treat "no significant increase found" in existing studies as reassuring but incomplete, not as proof of long-term safety.

When to seek urgent care rather than wait for the next lab draw

Sudden shortness of breath, chest pain, one-sided weakness or facial droop, calf swelling with pain, or very heavy unexpected vaginal bleeding are reasons to seek urgent evaluation rather than waiting for a scheduled lab visit, since some of these could reflect a clot, cardiovascular event, or a gynecologic problem that needs prompt assessment.

Monitoring decision framework

This table translates the guideline-level monitoring points above into a simple "what changes, and what to do" reference. It does not replace an individualized plan from the prescribing clinician.

Frequently asked questions

References

Earlier drafts referenced the Endocrine Society 2017 guideline, WPATH Standards of Care Version 8, UCSF Transgender Care guidelines, and cohort studies examining erythrocytosis, lipid changes, cardiovascular events, endometrial findings, and mental health outcomes. During this revision, linked identifiers for these sources could not be verified against primary literature. Any specific numeric data summarized in general form above requires verification against the original publications before use in patient-facing or clinical materials.